A Double-Blind Comparison of Escitalopram and Paroxetine in the Long-Term Treatment of Generalized Anxiety Disorder
| Autor: | Anjana Bose, Robert J. Bielski, Chung-Chi Chang |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Generalized anxiety disorder Citalopram law.invention Placebos Double blind Double-Blind Method Randomized controlled trial law Internal medicine mental disorders medicine Humans Escitalopram Adverse effect business.industry General Medicine Middle Aged medicine.disease Anxiety Disorders Paroxetine Clinical trial Psychiatry and Mental health Treatment Outcome Tolerability Anesthesia Female business Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Annals of Clinical Psychiatry. 17:65-69 |
| ISSN: | 1547-3325 1040-1237 |
| DOI: | 10.1080/10401230590932326 |
| Popis: | This study compared the efficacy and tolerability of escitalopram, a newer SSRI, with paroxetine in the treatment of generalized anxiety disorder (GAD).Patients with DSM-IV-defined GAD were randomized to receive 24 weeks of double-blind flexible-dose treatment with either escitalopram (10-20 mg/day) or paroxetine (20-50 mg/day), followed by a 2-week, double-blind, down-titration period. Mean change from baseline to endpoint (LOCF) in Hamilton Anxiety Scale (HAMA) scores was the primary efficacy variable.Mean baseline HAMA scores for the escitalopram (N = 60) and paroxetine (N = 61) groups were 23.7 and 23.4, respectively. After 24 weeks of treatment, mean changes in HAMA scores were -15.3 and -13.3 for escitalopram and paroxetine, respectively (p = 0.13). Significantly fewer patients withdrew from escitalopram than paroxetine treatment due to adverse events (6.6% vs. 22.6%; p = 0.02). The frequency of treatment-emergent adverse events was higher with paroxetine vs. escitalopram: overall (88.7% vs. 77.0%), insomnia (25.8% vs. 14.8%), constipation (14.5% vs. 1.6%), ejaculation disorder (30.0% vs. 14.8%), anorgasmia (26.2% vs. 5.9%), and decreased libido (22.6% vs. 4.9%). Conversely, diarrhea and upper respiratory tract infection were reported more with escitalopram than paroxetine (21.3% vs. 8.1%, and 14.8% vs. 4.8%, respectively).These results support the use of escitalopram as a first-line treatment for GAD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|